ArticleClinical and translational science2026
A Scoping Review of Non-Opioid Therapeutics for Opioid Withdrawal: Translational Relevance to Neonatal Opioid Withdrawal Syndrome (NOWS) Research.
Article in Clinical and translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In the wake of the ongoing opioid epidemic, the incidence of neonatal opioid withdrawal syndrome (NOWS) has surged. While the short-term effects of NOWS are well-characterized, long-term physiological and molecular consequences remain unclear. First-line NOWS treatments include non-pharmacological interventions; however, most infants who require medication are primarily treated with more opioids, such as morphine, weaned over time. This practice may be counterintuitive given recent preclinical evidence linking prenatal opioid exposure (POE) to neuroinflammation, as well as cognitive deficits in both preclinical and clinical studies. Identifying alternative non-opioid therapeutic agents may be essential for future NOWS management. This scoping review evaluated non-opioid therapeutics for opioid withdrawal symptoms (OWSx) across clinical and preclinical populations to identify candidate agents for future NOWS treatment research. Forty-one articles met inclusion criteria, encompassing 16 different drug classes, with particular attention to alpha-2-agonists, enzyme inhibitors, NMDA receptor antagonists, and unregulated dietary supplements. Among these empirical studies, several promising therapeutics emerged, with a few demonstrating efficacy on par with standard opioid treatments. However, despite promising results, definitive conclusions from many studies were limited by small sample sizes, inconsistent methodologies, or confounding variables. Furthermore, most agents remain untested in neonatal populations, leaving critical safety and dosing parameters unknown. This underscores the need for rigorous, translational research of these agents, including neonatal safety, efficacy, pharmacokinetics, and pharmacodynamics, ideally benchmarked against standard-of-care treatments. Addressing these gaps is crucial for developing effective NOWS treatment and improving outcomes for this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.